Elective sirolimus-eluting stent implantation for left main coronary artery disease: six-month angiographic follow-up and 1-year clinical outcome

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Chourmouzios A ArampatzisPatrick W Serruys

Abstract

The effectiveness of sirolimus-eluting stent (SES) implantation in patients treated electively for left main (LM) stenoses has not been yet ascertained. The present study reports on the clinical and angiographic outcome of 16 consecutive patients treated electively for de novo stenoses in the LM. The impact of SES implantation on major adverse cardiac events was evaluated. Mean age was 65 +/- 11 years. Unprotected LM was present in nine (56%), and eight patients (50%) received stents extending into both the left anterior descending and circumflex arteries for stenoses of the distal left main bifurcation. In-house mortality and reintervention rate was zero. One patient developed a non-Q-wave myocardial infarction related to the index procedure. At 1-year clinical follow-up, there were no deaths or further myocardial infarctions; one (6%) patient required target lesion revascularization. A total of 12 patients (75%) underwent 6-month angiographic follow-up with a late lumen loss of 0.04 +/- 0.65 mm and one focal restenosis (8% of patients). Elective SES implantation for LM disease was associated with zero mortality and a very low incidence of additional major adverse events at 1 year.

References

May 12, 2000·Journal of the American College of Cardiology·D S Baim
Jun 7, 2002·The New England Journal of Medicine·Marie-Claude MoriceUNKNOWN RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patie
Jul 31, 2003·The American Journal of Cardiology·Chourmouzios A ArampatzisPatrick W Serruys

❮ Previous
Next ❯

Citations

Feb 27, 2007·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Stefan BrunnerWolfgang-Michael Franz
May 26, 2005·Current Treatment Options in Cardiovascular Medicine·William W Chu, Ron Waksman
Aug 27, 2005·Nature Clinical Practice. Cardiovascular Medicine·Alaide Chieffo, Antonio Colombo
Dec 19, 2006·Cardiology in Review·Leo SlavinJonathan M Tobis
Nov 17, 2006·Expert Opinion on Investigational Drugs·Nusrat ShafiqYash Paul Sharma
Mar 27, 2007·Current Problems in Cardiology·Ayman A El-MenyarDavid R Holmes
Aug 3, 2006·Journal of Interventional Cardiology·Eric LaroseDaniel I Simon
Jan 4, 2006·Current Problems in Cardiology·Amar M SalamDavid R Holmes
Sep 11, 2007·The American Journal of Cardiology·Marcelo SanmartínAndrés Iñiguez
Feb 1, 2005·Journal of the American College of Cardiology·Seung-Jung ParkSeong-Wook Park
May 10, 2006·Journal of the American College of Cardiology·Patrick W Serruys
May 16, 2006·Journal of the American College of Cardiology·Angela HoyeAntonio Colombo
Apr 6, 2005·Journal of the American College of Cardiology·William W O'NeillCindy L Grines
Mar 17, 2005·European Heart Journal·Sigmund SilberUNKNOWN Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Aug 8, 2006·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Michael RagostaEric R Powers
Jun 10, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Frances WoodTift Mann
Sep 10, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Yoshinobu MurasatoFumihiko Kamezaki
Sep 13, 2005·Cardiology·Sang Hak LeeUNKNOWN Korean Multicenter Angioplasty Team (KOMATE) Investigators
Nov 8, 2005·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Saskia Z H RittersmaRobbert J de Winter
Mar 3, 2006·Expert Review of Cardiovascular Therapy·Sophia VainaPatrick W Serruys

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.